|
|
|
|
|
|
|
||||
| Home Help Feedback Subscriptions Archive Search Table of Contents | ||||
|
Fig. 8. Antisense morpholinos against XHRT1 reduces the expression of glomus and
proximal tubule markers. (A) Design of the XHRT1-MO that targets
both pseudoalleles. (Bottom) In vivo translation of XHRT1a-eGFP is
specifically inhibited by XHRT1-MOs. Embryos were injected with 500 pg of
XHRT1-eGFP or eGFP mRNA, alone or in combination with 15 ng
of the XHRT1-MO, as indicated. (B-O) Embryos injected with 15 ng
XHRT1-MO and ß-galactosidase mRNA analysed with the indicated markers.
(B-I) Control and injected sides of XHRT1-MO-injected embryos with decreased
XSMP-30, xPDZK1, xWT1 and nephrin expression. (J,K)
Transversal sections of XHRT1-MO-injected embryos. (L,M) XHRT1 knockdown has
no effect on Evi1 expression. (N,O) Transversal sections of
XHRT1-MO-injected embryos. Ep. keratin and N-tubulin
expression is unaffected by XHRT1 knockdown. (P) Co-injection of the
XHRT1-MO with 500 pg of XHRT1a-mut-MT-hGR mRNA rescues
XSMP-30 expression in stage 22 dexamethasone-treated
XHRT1-MO-injected embryos. Changes in the expression of XSMP-30 were
scored and classified as in Fig.
6A. (Q) Co-injection of 15 ng XHRT1-MO inhibits the effect
of overexpression of hGR/Su(H)/Ank (500 pg) on XSMP-30
expression. Injected embryos were dexamethasone treated at stage 22. Changes
in the expression of XSMP-30 were classified into two groups (no
change or increase, decrease). n, number of embryos analysed; m,
medial intermediate mesodermal layer; pn, pronephros; pt, pronephric
tubules.
|
